The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study

Journal of the National Cancer Institute

Volumn 109, Issue 9, 2017, Pages

  Carreras Torres, Robert ^a   Johansson, Mattias ^a   Gaborieau, Valerie ^a   Haycock, Philip C ^b   Wade, Kaitlin H ^b   Relton, Caroline L ^b   Martin, Richard M ^b,c   Smith, George Davey ^b   Brennan, Paul ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; METABOLIC RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS CANCER; PLEIOTROPY; RISK FACTOR; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST HIP RATIO; CASE CONTROL STUDY; COMPLICATION; ENERGY METABOLISM; GENETIC PREDISPOSITION; HEALTH SURVEY; META ANALYSIS; METABOLISM; ODDS RATIO; PANCREATIC NEOPLASMS; QUANTITATIVE TRAIT; STATISTICAL MODEL;

BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INSULIN; INSULIN RESISTANCE; LIKELIHOOD FUNCTIONS; MALE; OBESITY; ODDS RATIO; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION SURVEILLANCE; QUANTITATIVE TRAIT, HERITABLE; RISK FACTORS;

EID: 85020432786     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djx012     Document Type: Article

References (46)

1. Torre LA, Bray F, Siegel RL, Ferlay J. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–347.
3. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–798.
4. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. 2007. http://www.aicr.org/assets/docs/pdf/reports/Second_Expert_Report.pdf. Accessed March 24, 2017.
5. Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: An analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23:280–284.
6. Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: A summary review of meta-analytical studies. Int J Epidemiol. 2015;44(1):186–198.
7. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–578.
8. Aune D, Greenwood DC, Chan DSM, et al. Body mass index, abdominal fatness and pancreatic cancer risk: A systematic review and non-linear dose—response meta-analysis of prospective studies. Ann Oncol. 2012;23:843–852.
9. Urayama KY, Holcatova I, Janout V, et al. Body mass index and body size in early adulthood and risk case—control study. Int J Cancer. 2011;129: 2875–2884.
10. Aune D, Rita A, Doris V, Man S, Norat T. Height and pancreatic cancer risk: A systematic review and meta-analysis of cohort studies. Cancer Causes Control. 2012;23:1213–1222.
11. Chen H, Qin S, Wang M, Zhang T, Zhang S. Association between cholesterol intake and pancreatic cancer risk: Evidence from a meta-analysis. Sci Rep. 2015;5:8243–8248.
12. Liao W-C, Tu Y-K, Wu M-S, Lin J-T, Wang H-P, Chien K-L. Blood glucose concentration and risk of pancreatic cancer: Systematic review and dose-response meta-analysis. BMJ. 2015;349:g7371.
13. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem. 2008;114:63–70.
14. Elena JW, Steplowski E, Yu K, et al. Diabetes and risk of pancreatic cancer: A pooled analysis from the pancreatic cancer cohort consortium. Cancer causes Control. 2013;24:13–25.
15. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–2083.
16. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: A systematic review and meta-analysis. Diabetes Care. 2012;35:2402–2411.
17. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;(32):1–22.
18. Davey Smith G, Hemani G. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(1):1–10.
19. Burgess S, Butterworth AS, Thompson JR. Beyond Mendelian randomization: How to interpret evidence of shared genetic predictors. J Clin Epidemiol. 2016; 69:208–216.
20. Petersen GM, Amundadottir L, Fuchs CS, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010;42(3):224–228.
21. Amundadottir L, Kraft P, Stolzenberg-solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41(9):986–990.
22. Childs EJ, Mocci E, Campa D, et al. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet. 2015;47(8):911–916.
23. Tryka KA, Hao L, Sturcke A, et al. NCBI’s database of genotypes and phenotypes: DbGaP. Nucleic Acids Res. 2014;42(D1):975–979.
24. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013; 37(7):658–665.
25. Burgess S, Scott RA, Timpson NJ, Davey-smith G, Thompson SG. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2014;(100114):1–39.
26. Wood AR, Esko T, Yang J, et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet. 2014; 46(11):1173–1186.
27. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.
28. Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518:187–196.
29. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274–1283.
30. Scott RA, Lagou V, Welch RP, Wheeler E, May E. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44(9):991–1005.
31. Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):981–989.
32. Gaulton KJ, Ferreira T, Lee Y, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015;47(12):1415–1425.
33. Michigan Imputation Server. https://imputationserver.sph.umich.edu/index.html. Accessed March, 2016.
34. Delaneau O, Marchini J, Zagury J-F. A linear complexity phasing method for thousands of genomes. Nat Methods. 2012;9:179–181.
35. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through prephasing. Nat Genet. 2012;44(8):955–959.
36. Haplotype Reference Consortium. http://www.haplotype-reference-consortium.org/home. Accessed March 24, 2017.
37. Willer CJ, Li Y, Abecasis GR. METAL: Fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190–2191.
38. Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol. 2014;43(3):922–929.
39. Bowden J, Smith GD, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–314.
40. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–525.
41. Braun S, Bitton-worms K, Leroith D. The link between the metabolic syndrome and cancer. Int J Biol Sci. 2011;7(7):1003–1015.
42. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4): 473–481.
43. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: New mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484–498.
44. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218–1249.
45. Pothiwala P, Jain SK, Ph D, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord. 2009;7(4):279–288.
46. Ammon HPT. Hyper- and hypoinsulinemia in type-2 diabetes: What may be wrong in the secretory mechanism of the B-cell. Exp Clin Endocrinol Diabetes. 1997;105(suppl 2):43–47.